Panacea Biotec

Innovation in support of life

11th September, 2016

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol : PANACEABIO

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Fax No.:022–22721919, 3121
BSE Scrip Code: 531349

Reg.: i. Unaudited Financial Results (Provisional) for the quarter and half year ended 30th September, 2016

ii. Limited Review Report for the quarter and half year ended 30th September, 2016

Dear Sir,

In continuation to our letter dated 25th October, 2016 and pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we would like to inform you that the Board of Directors of the Company has, at its meeting held on today, i.e. 11th November, 2016, inter-alia, considered and approved the Unaudited Financial Results (Provisional) for the quarter and half year ended 30th September, 2016. The same were also reviewed by the Audit Committee in its meeting held on 10th November, 2016.

A copy of the Statement of Unaudited Financial Results (Provisional) for the quarter and half year ended 30th September, 2016, approved by the Board pursuant to Listing Regulations, is enclosed for your reference and record.

Further, we would also like to state that M/s Walker Chandiok & Co. LLP, Chartered Accountants, the Statutory Auditors of the Company have carried out the limited review of the Unaudited Financial Results (Provisional) for the quarter and half year ended 30th September, 2016 and the Board has also taken on record their Limited Review Report on the said Results. A copy of the said report is attached herewith for your records.

Further, pursuant to Regulation 46(2)(l) of Listing Regulations, the said financial results are being uploaded on the website of the Company i.e. www.panaceabiotec.com.

Further, pursuant to Regulation 47(1)(b) of Listing Regulations, the Extract of Statement of Unaudited Financial Results (Provisional) for the quarter and half year ended 30th September, 2016 in the Format as prescribed in Annexure XI of SEBI Circular No. CIR/CFD/CMD/15/2015 dated 30.11.2015 is being sent for publication in newspapers.

Contd.....2/-

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9075

Panacea Biotec

Innovation in support of life

The meeting of the Board of Directors commenced at 11.30 A.M. and concluded at 04.30 P.M.

We request you to kindly bring the above information to the notice of your members.

Thanking you,

Sincerely yours,
for Panacea Biotec Ltd.

Vinod Goel
Group CFO and Head Legal & Company Secretary

Encls: As above.

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9075

(Rs. in Lacs except per share)

Panacea Biotec
Innovation in support of life

Extract of Standalone Unaudited Financial Results for the Quarter and Half year ended September 30, 2016

Particulars	Quarter Ended			Half Year Ended		Year Ended
	September 30, 2016	June 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015	March 31, 2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total income from operations (net)	13,716	12,367	16,477	26,083	28,961	64,690
Net Profit / (Loss) from ordinary activities after tax	(1,184)	(1,967)	(1,700)	(3,151)	(5,390)	87
Net Profit / (Loss) for the period after tax (after Extraordinary items)	(1,184)	(1,967)	(1,700)	(3,151)	(5,390)	87
Equity Share Capital (face value of Re.1 per share)	613	613	613	613	613	613
Reserves (excluding Revaluation Reserve as shown in the Balance Sheet)	-	-	-	-	-	10751
Earning per Share (before and after extraordinary items) of Re. 1 each (annualised, other than Quarter)						
Basic :	(1.93)	(3.21)	(2.77)	(5.14)	(8.80)	0.14
Diluted:	(1.93)	(3.21)	(2.77)	(5.14)	(8.80)	0.14

Notes:

1 The above is an extract of the detailed format of quarterly and half yearly results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly results are available on the Stock Exchange websites, NSE- http://www.nseindia.com, BSE- http://www.bseindia.com and are also available on the Company's website, http://www.panaceabiotec.com.

2 The above extract of financial results were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their respective meetings held on November 10, 2016 and November 11, 2016 respectively.

3 Previous period / year amounts have been regrouped/ reclassified to make them comparable with those of current period/year.

For and on behalf of the Board

Dr. Rajesh Jain
Joint Managing Director

New Delhi
November 11, 2016

Panacea Biotec Limited
Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab
CIN: L33117PB1984PLC022350 - Ph. No. 91-11-41679000, Fax: 91-11-41679070,Website: http://www.panacea-biotec.com - E-mail: Corporate@panaceabiotec.com

Panacea Biotec
Innovation in support of life

Statement of Standalone unaudited financial results for the quarter and half year ended on September 30, 2016

(Rs. in Lac)

Particulars	For the quarter ended			For the half year ended		For the year ended
	September 30, 2016	June 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015	March 31, 2016
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
PART - I						
1. Income from operations						
a. Gross sales / income from operations	13,577	12,224	16,112	25,801	28,196	62,002
Less:- Excise Duty	421	184	13	605	20	36
Net sales / income from operations	13,156	12,040	16,099	25,196	28,176	61,966
b. Other operating income	560	327	378	887	785	2,724
Total income from operations (net)	13,716	12,367	16,477	26,083	28,961	64,690
2. Expenditure						
a. Cost of materials consumed	3,462	3,878	5,242	7,340	8,445	16,882
b. Purchase of stock in trade	710	507	702	1,217	1,348	2,402
c. Changes in inventories of finished goods, work in progress and stock in trade	459	(576)	118	(117)	423	2,151
d. Employees benefits expense	3,556	3,353	3,670	6,909	7,189	13,980
e. Depreciation and amortisation expenses	1,659	1,662	1,768	3,321	3,623	7,132
f. Other expenses	4,504	4,131	4,243	8,635	8,207	18,024
Total expenses	14,350	12,955	15,743	27,305	29,235	60,571
3. Profit/ (Loss) from operations before other income, finance cost & exceptional items (1-2)	(634)	(588)	734	(1,222)	(274)	4,119
4. Other income	2,001	1,122	737	3,123	1,104	2,556
5. Profit / (Loss) from ordinary activities before finance cost & exceptional items (3+4)	1,367	534	1,471	1,901	830	6,675
6. Finance cost	2,551	2,501	3,171	5,052	6,220	11,500
7. Profit / (Loss) from ordinary activities after finance cost before exceptional items (5-6)	(1,184)	(1,967)	(1,700)	(3,151)	(5,390)	(4,825)
8. Exceptional items	-	-	-	-	-	4,965
9. Profit / (Loss) from ordinary activities before tax (7+8)	(1,184)	(1,967)	(1,700)	(3,151)	(5,390)	140
10. Tax expenses	-	-	-	-	-	53
11. Net profit / (loss) from ordinary activities after tax (9-10)	(1,184)	(1,967)	(1,700)	(3,151)	(5,390)	87
12. Extraordinary items (net of tax expenses)	-	-	-	-	-	-
13. Net profit / (loss) for the period (11-12)	(1,184)	(1,967)	(1,700)	(3,151)	(5,390)	87
14. Paid up equity share capital (face value of Re.1 per share)	613	613	613	613	613	613
15. Reserves excluding revaluation reserves	-	-	-	-	-	10,751
16. Earning per share (EPS) (before/after extraordinary items) of Re. 1 each (annualised, other than Quarter)						
- Basic (in Rs.)	(1.93)	(3.21)	(2.77)	(5.14)	(8.80)	0.14
- Diluted (in Rs.)	(1.93)	(3.21)	(2.77)	(5.14)	(8.80)	0.14

Unaudited Segment-wise Revenue , Results, Assets, Liability and Capital Employed for the quarter and half year ended on September 30, 2016

Particulars	For the quarter ended			For the half year ended		For the year ended
	September 30, 2016	June 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015	March 31, 2016
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.Segment revenue						
(a) Vaccines	3,261	3,132	5,658	6,393	8,200	25,318
(b) Formulations	10,340	9,195	10,812	19,535	20,683	38,065
(c) Research & development	115	40	7	155	78	1,307
(d) Unallocated	-	-	-	-	-	-
Gross sale/income from operation	13,716	12,367	16,477	26,083	28,961	64,690
Less : Inter segment revenue	-	-	-	-	-	-
Net sales/income from operations	13,716	12,367	16,477	26,083	28,961	64,690
2.Segment results						
Profit (+)/ loss (-) before tax and interest from each segment						
(a) Vaccines	(453)	386	859	(67)	(387)	6,669
(b) Formulations	3,732	2,832	3,768	6,564	7,357	10,929
(c) Research & development	(1,642)	(1,209)	(1,598)	(2,851)	(3,224)	(5,177)
Total	1,637	2,009	3,029	3,646	3,746	12,421
Less : i) Interest expenses (including bank charges etc.)	2,551	2,501	3,171	5,052	6,220	11,500
ii) Other un-allocated expenditure net off un-allocated income	270	1,475	1,558	1,745	2,916	781
Total profit before tax	(1,184)	(1,967)	(1,700)	(3,151)	(5,390)	140
3A.Segment assets						
(a) Vaccines	58,591	59,086	61,721	58,591	61,721	61,540
(b) Formulations	41,633	40,066	39,933	41,633	39,933	39,549
(c) Research & development	21,400	20,789	21,592	21,400	21,592	21,707
(d) Unallocated	56,898	57,895	59,201	56,898	59,201	57,947
Total	178,522	177,836	182,447	178,522	182,447	180,743
3B.Segment liabilities						
(a) Vaccines	3,864	2,964	3,936	3,864	3,936	3,825
(b) Formulations	15,043	13,217	13,906	15,043	13,906	12,707
(c) Research & development	2,490	2,378	2,591	2,490	2,591	2,230
(d) Unallocated	105,900	107,304	113,788	105,900	113,788	107,978
Total	127,297	125,863	134,221	127,297	134,221	126,740
3C.Capital Employed						
(Segment assets-segment liabilities)						
(a) Vaccines	54,727	56,122	57,785	54,727	57,785	57,715
(b) Formulations	26,590	26,849	26,027	26,590	26,027	26,842
(c) Research & development	18,910	18,411	19,001	18,910	19,001	19,477
(d) Unallocated	(49,002)	(49,409)	(54,587)	(49,002)	(54,587)	(50,031)
Total capital employed	51,225	51,973	48,226	51,225	48,226	54,003

Statement of Assets & Liabilities

(Rs. in Lac)

Particulars	Standalone as on	
	September 30, 2016 (Unaudited)	March 31, 2016 (Audited)
Equity and liabilities		
Shareholders' funds		
Share capital	2,243	2,243
Reserves and surplus	48,982	51,760
	51,225	54,003
Non-current liabilities		
Long term borrowings	70,997	77,888
Deferred tax liabilities (Net)	-	-
Other long term liabilities	-	34
Long term provisions	1,500	1,418
	72,497	79,340
Current liabilities		
Short-term borrowings	22,190	21,825
Trade payables	19,679	17,383
Other current liabilities	12,784	8,055
Short-term provisions	147	137
	54,800	47,400
Total	178,522	180,743
Assets		
Non current assets		
Fixed assets		
Tangible assets	94,885	97,619
Intangible assets	711	1,139
Capital work-in-progress	1,122	865
Intangible assets under development	1,876	1,036
Non-current investments	39,517	39,466
Loans and advances	6,665	6,682
Other non current assets	14	55
	144,790	146,862
Current assets		
Inventories	12,997	13,657
Trade receivables	11,839	14,221
Cash and bank balances	852	932
Short-term loans and advances	7,626	4,536
Other current assets	418	535
	33,732	33,881
Total	178,522	180,743

1	The above financial results were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their respective meetings held on November 10, 2016 and November 11, 2016 respectively. Further, the Limited Review of above Financial Results in terms of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors.
2	During the Quarter ended September 30, 2016, the Company has launched anti-diabetic drug TENEPAN M 500/1000mg (Teneligliptin and Metformin), for treatment of Type 2 Diabetes Mellitus (T2DM).
3	Other income includes Rs.1,377 Lac (including Rs.210 Lac as prior period item) on account of reversal of excess provision created in earlier years.
4	Corporate Debt Restructuring:
a	During financial year 2014-15, the Company was sanctioned a Corporate Debt Restructuring ("CDR") scheme under the CDR mechanism of the Reserve Bank of India ("RBI") after attaining super-majority from its lender banks. The Company executed a Master Restructuring Agreement ("MRA") with all the lender banks except State Bank of Travancore ("SBT") on December 27, 2014, with Cut-off Date of October 01, 2013. The MRA, inter-alia, provides for waiver of certain existing obligations of the Company, restructuring of repayment terms for principal and interest, reduction/adjustment in interest rates, conversion of outstanding interest amounts to loan, pledge of entire promoter shareholding as additional security to lenders, promoter undertaking for additional infusion of funds, monitoring oversight and certain restrictive covenants, as defined therein. The debt obligations, including interest thereon, have been measured, classified and disclosed in these financial statements in accordance with the MRA, to the extent agreed with the banks. Completion of certain other terms and conditions are in process.
b	During the financial year 2015-16, State Bank of Mysore had absolutely assigned all the rights, title and interests in financial assistances granted to the Company, with all the underlying rights, benefits and obligations in favour of Edelweiss Asset Reconstruction Company Ltd. ("EARC") vide assignment letter dated February 26, 2016. The Company is negotiating the terms of restructuring of such outstandings, with EARC.
5	With respect to the observations of the auditors in their report on the above results:
a	During the half year ended September 30, 2016, the Company has incurred a loss of Rs.3,151 Lac (Previous financial year: Profit of Rs.87 Lac) including exceptional income of Rs.Nil (Previous financial year Rs.4,965 Lac). The continuous losses have also adversely affected the cash flows of the Company. These conditions, read with note 4 above, indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. The Company has undertaken several measures to mitigate this risk, which include supply to UNICEF/other customers of pentavalent vaccine; certain strategic alliances with domestic as well foreign collaborators for supply of products, launch of new products etc. Additionally, further to note 4 above, the management is confident that it will be able to comply with all key conditions of the CDR scheme. Based on above measures and continuous efforts to improve the business, the management believes that it would be able to generate sustainable cash flow, recover and recoup the erosion in its net worth through profitable operations, discharge its obligations as they fall due and continue as a going concern.
b	In view of absence of profits during financial years 2013-14 and 2012-13, total remuneration to the Managing/Joint Managing and Whole time Directors had exceeded the ceiling prescribed in Section II of Part II of Schedule XIII to the Companies Act, 1956 by Rs.135.6 Lac and Rs.132.1 Lac respectively. Accordingly, applications for protection/approval of the Central Government for such excess remuneration have been filed and requisite approvals are awaited. The management is hopeful of receiving necessary approval from Central Government.
6	The necessary certificate/report in respect of the above results in terms of requirement of Regulation 33 and Regulation 17(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors.
7	Previous period / year amounts have been regrouped/ reclassified to make them comparable with those of current period/year.
8	The above results are also available on the Company's website http://www.panaceabiotec.com

For and on behalf of the Board

Dr. Rajesh Jain
Joint Managing Director

New Delhi
November 11, 2016

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP
(Formerly Walker, Chandiok & Co)
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurgaon 122002
India

T +91 124 462 8000
F +91 124 462 8001

Review Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Panacea Biotec Limited


1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Panacea Biotec Limited ("the Company") for the quarter ended 30 September 2016 and the year to date results for the period 1 April 2016 to 30 September 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards, as notified under the Companies (Accounting Standards) Rules, 2006 (as amended) read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to0020be disclosed, or that it contains any material misstatement.

4. We draw attention to Note 5(b) to the Statement regarding payment of managerial remuneration of Rs. 375 lacs and Rs. 372 lacs for the financial years ended 31 March 2014 and 2013 respectively, which is in excess of the limits specified by the relevant provisions of the Companies Act, 1956, by Rs. 135 lacs and Rs. 132 lacs respectively. The Company has filed necessary application to the Central Government which is pending approval as on date. Pending the ultimate outcome of the aforesaid matter which is presently unascertainable, no adjustments have been recorded in the statement. Our review report is not qualified in respect of this matter.





Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

Review report to the Board of Directors of Panacea Biotec Limited on the financial results for the quarter ended 30 September 2016 (Cont'd)

5. We draw attention to note 5(a) to the Statement which indicates that the Company has incurred a net loss of Rs. 1,184 lacs and Rs. 3,151 lacs during the quarter and half year ended 30 September 2016, respectively. Further, as of that date, the Company's current liabilities exceeded its current assets by Rs. 21,069 lacs. These conditions along with other matters as set forth in aforesaid note indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Our review report is not qualified in this respect of this matter.

Walker Chandiok & Co LLP

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

per **Rajesh Jain**
Partner
Membership No. 081203

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS

Place: Gurgaon
Date: 11 November 2016